UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Erlotinib

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A1	OCT1	Erlotinib	86		1-methyl-4-phenylpyridinium (MPP+)	HEK293-OCT1	Johnston, 2014
SLC22A1	OCT1	Erlotinib	16.24		4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+)	HEK293-OCT1	Chen, 2017
SLCO2B1	OATP2B1, OATP-B	Erlotinib	0.07		Dibromofluorescein	HEK293-OATP2B1	Unger, 2020
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Erlotinib	21	21	Estradiol-17beta-glucuronide	HEK-OATP1B1	Karlgren, 2012
SLCO1B3	OATP1B3, OATP8	Erlotinib	44	41	Estradiol-17beta-glucuronide	HEK293-OATP1B3	Karlgren, 2012
ABCG2	BCRP, MXR	Erlotinib	0.13	0.15	Estrone sulfate	BCRP-expressing K562 vesicles	Noguchi, 2009
SLC22A1	OCT1	Erlotinib	0.356		Metformin	HEK293-OCT1	Minematsu, 2011
SLC47A1	MATE1	Erlotinib	8		Metformin	HEK293-MATE1	Minematsu, 2011
SLC47A2	MATE2K	Erlotinib	3.45		Metformin	HEK293-MATE2K	Minematsu, 2011
ABCB1	MDR1, P-gp	Erlotinib	2		Vincristine	MDR1-expressing K562 vesicles	Noguchi, 2009

No drug-drug interaction information.